115479-40-8

Usage

Uses

Used in Organic Synthesis:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of a wide range of derivatives, making it a versatile building block in the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is used as a starting material for the synthesis of novel drug candidates. Its chemical properties and functional groups can be exploited to design and develop new therapeutic agents with improved efficacy and selectivity.
Used in Chemical Research:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is also used in chemical research to study the reactivity and properties of various functional groups. Its unique structure provides a platform for investigating new reaction pathways and understanding the fundamental principles of organic chemistry.
Chemical Properties:
2-Amino-4-chloro-7-(2,3-O-isopropylidene-5-O-tert-butyldimethylsily--D-ribofuranosyl)pyrrolo[2,3,-d]pyrimidine is a foamy solid, indicating that it has a low melting point and is likely to be sensitive to heat and moisture. This property should be taken into consideration during its synthesis, storage, and handling to ensure the stability and purity of the compound.

InChI:InChI=1/C20H31ClN4O4Si/c1-19(2,3)30(6,7)26-10-12-13-14(29-20(4,5)28-13)17(27-12)25-9-8-11-15(21)23-18(22)24-16(11)25/h8-9,12-14,17H,10H2,1-7H3,(H2,22,23,24)/t12-,13+,14+,17-/m1/s1

Upstream product

• 102690-94-8 2,3-O-isopropylidene-5-O-(tert-butyldimethylsilyl)-α-D-ribofuranosyl chloride 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 102690-95-9 5-O-<(1,1-dimethylethyl)dimethylsilyl>-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl chloride 
• 217309-46-1 5-(tert-butyldimethylsilyloxy)-2,3-isopropylidenedioxy-D-ribofuranose 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 532-20-7 D-Ribose 

Downstream Products

• 62160-23-0 2-amino-7-β-D-ribofuranosylpyrrolo<2,3-d>pyrimidin-4(3H)-one 
• 115479-42-0 2-Amino-4-methoxy-7-β-D-ribofuranosylpyrrolo<2,3-d>pyrimidine 
• 62160-23-0 7-deazaguanosine 
• 444019-16-3 2-[(4-monomethoxytrityl)amino]-7-(2-O-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one 
• 444019-20-9 2-[(p-anisyldiphenylmethyl)amino]-7-(3-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one 
• 131981-22-1 7-{5'-O-[(1,1-dimethylethyl)dimethylsilyl]-2',3'-O-(1-methylethylidene)-β-D-ribofuranosyl}-4-methoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 120401-36-7 2-amino-4-chloro-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 

Relevant academic research and scientific papers

Synthesis and Properties of 2′-OMe-RNAs Modified with Cross-Linkable 7-Deazaguanosine Derivatives

Cross-linkable 7-deaza-6-vinylguanosine (ADVP) and 7-propynyl-7-deaza-6-vinylguanosine (ADpVP) derivatives were synthesized and successfully incorporated into 2′-OMe-RNA oligonucleotides by solid-phase oligonucleotide synthesis. Analysis of their cross-li

2-substituted 6-(het)aryl-7-deazapurine ribonucleosides: Synthesis, inhibition of adenosine kinases, and antimycobacterial activity

Abstract A series of 6-(hetero)aryl- or 6-methyl-7-deazapurine ribonucleosides bearing a substituent at position 2 (Cl, F, NH2, or CH3) were prepared by cross-coupling reactions at position 6 and functional group transformations at p

S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS

Various embodiments provide STOPS? polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS? modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS? modified oligonucleotides, as determined by HBsAg Secretion Assay, is an EC50 that is less than 100 nM.

C6–O-alkylated 7-deazainosine nucleoside analogues: Discovery of potent and selective anti-sleeping sickness agents

African trypanosomiasis, a deadly infectious disease caused by the protozoan Trypanosoma brucei spp., is spread to new hosts by bites of infected tsetse flies. Currently approved therapies all have their specific drawbacks, prompting a search for novel th

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE

The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

Synthesis and evaluation of S-Acyl-2-thioethyl esters of modified nucleoside 5′-monophosphates as inhibitors of hepatitis C virus RNA replication

Several triphosphates of modified nucleosides (1-6) were identified as inhibitors (IC50 -0.08-3.8 μM) of hepatitis C virus RNA-dependent RNA polymerase (RdRp). Although the initial SAR developed by determining the ability of the triphosphates t

OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS

Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

A facile and improved synthesis of tubercidin and certain related pyrrolo[2,3-d]pyrimidine nucleosides by the stereospecific sodium salt glycosylation procedure [1]

A simple synthesis of tubercidin, 7-deazaguanosine and 2'-deoxy-7-deazaguanosine has been accomplished using the sodium salt glycosylation procedure. Reaction of the sodium salt of 4-chloro- and 2-amino-4-chloro-pyrrolo[2,3-d]pyrimidine, 3 and 4, respectively, with 1-chloro-2,3-O-isopropylidene,5-O-(t-butyl)dimethylsilyl-α-D-ribofur nose gave the corresponding protected nucleosides 6 and 7 with β-anomeric configuration. Deprotection of 6 provided 8, which on heating with methanolic ammonia gave tubercidin in excellent yield. Functional group transformation of 7, followed by deisopropylidenation gave 2-aminotubercidin and 2-amino-7-β-ribofuranosylpyrrolo[2,3-d]pyrimidine-4(3H)-thione. Treatment of 7 with 1N sodium methoxide followed by exposure to aqueous trifluoroacetic acid, and ether cleavage furnished 7-deazaguanosine. 2'-Deoxy-7-deazaguanosine and 2'-deoxy-7-deaza-6-thioguanosine were also prepared by using similar sequence of reactions employing 4 and 1-chloro-2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranose.